CAMBRIDGE, Massachusetts, August 27, 2026, 10:15 (EDT) Moderna (MRNA.O) stock slid 5.0% on Thursday, shaving $3.0 billion off its market value, after the company announced a $2 billion convertible notes sale, testing investor appetite following a recent rally in its cancer-vaccine business.
- Shares of Moderna declined 5.0% to $142.20 during Thursday morning trade.
- The firm put forward an offering of $2.0 billion in convertible notes maturing in 2032, along with an additional $300 million option.
- The share decline wiped out around $3.0 billion in equity value, roughly 1.48 times the initial offering size.
- The core agreement represents 28.9% of Moderna’s cash and investments as of June 30.
Shares of Moderna Inc. dropped 5.0% following the vaccine producer’s announcement of a $2.0 billion convertible-note offering. At 10:15:13 a.m. EDT, the stock was at $142.20, with 7.34 million shares traded. The day’s trading range spanned from $137.95 to $150.70 NASDAQ:MRNA market data.
The drop brought Moderna’s market value down to approximately $56.54 billion, erasing nearly $3.0 billion from its closing value on Wednesday. This decrease amounted to about 1.48 times the intended base financing.
The notes on offer will mature in 2032. These are senior unsecured securities without periodic interest payments and no increase in principal over time. Initial buyers also have the option to acquire an additional $300 million within a 13-day period Moderna financing announcement.
Final terms for conversion will be determined at pricing. Moderna can choose to settle conversions using cash, stock, or a combination. This arrangement does not include a fixed cash coupon but could result in dilution if the stock appreciates and Moderna opts to pay in shares.
Moderna is arranging capped-call transactions in conjunction with the offering. These hedges aim to reduce dilution, with a ceiling set at no less than 150% above the pricing reference. The net proceeds could be used for expanding oncology efforts, debt repayment, and other general corporate aims.
| Investor measure | Verified amount | Financing context |
|---|---|---|
| MRNA latest price | $142.20, off 5.0% | 10:15:13 a.m. EDT |
| Calculated equity-value drop | Roughly $3.0 billion | 1.48× base notes |
| Base / cap notes | $2.0 billion / $2.3 billion | Maturing 2032 |
| Cash and investments at June 30 | $6.9 billion | Base notes comprise 28.9% |
| Q2 cash burn from operations | $526 million | Base notes are 3.8× |
| Q2 net deficit | $782 million | Base notes are 2.6× |
The timing can be understood by looking at the balance sheets. As of June 30, Moderna’s cash, cash equivalents and investments totaled $6.9 billion. In July, the company paid $950 million related to a litigation settlement second-quarter results.
Moderna reported second-quarter revenue of $145 million, compared to $142 million in the same period last year. The company recorded a net loss of $782 million, equating to a loss of $1.97 per share. Operating cash outflow totaled $526 million.
The base offering amounts to 3.8 quarters of cash consumption at the most recent quarterly rate. It also represents 28.9% of reported June liquidity. These figures do not include financing expenses, capped-call outlays or the July settlement payment.
The sale comes after an eight-day rally in cancer-vaccine stocks. On August 19, Moderna and Merck disclosed positive Phase 3 melanoma results, prompting a shift in expectations for Moderna’s oncology pipeline company-news chronology. Thursday’s financing aims to convert some of that renewed market value into operating flexibility.
Wall Street is taking a careful stance following the rally. The consensus among 23 analysts stands at Hold, and their average price target is $104.53. This projection is roughly 26.5% lower than the price seen on Thursday analyst consensus.
Risks: The offering is still dependent on market conditions. Greater dilution could result from a reduced conversion premium or a higher share settlement. Delays or failures in oncology trials, regulatory approval, or commercialization efforts would also undermine the case for raising funds following the recent rally.
Pricing comes next. Investors are awaiting details on the conversion rate, capped-call expense and net proceeds. This information will indicate the amount of capital Moderna raised relative to each potential unit of dilution.
Related articles: NASDAQ:MRNA
